Revvity, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Revvity, Inc. has filed its 2023 Form 10-K, detailing its financial position and business operations.</b>

AI Summary

REVVITY, INC. (RVTY) filed a Annual Report (10-K) with the SEC on February 27, 2024. Revvity, Inc. reported total assets of $14,697,780,722 for the fiscal year ended December 31, 2023. The company's fiscal year ends on December 29th. Revvity, Inc. was formerly known as PerkinElmer Inc. The company's SIC code is 3826 for Laboratory Analytical Instruments. Revvity, Inc. is incorporated in Massachusetts.

Why It Matters

For investors and stakeholders tracking REVVITY, INC., this filing contains several important signals. This filing provides a comprehensive overview of Revvity's financial health and strategic direction for investors and stakeholders. As a 10-K filing, it contains audited financial statements and critical disclosures about the company's business, risks, and management.

Risk Assessment

Risk Level: medium — REVVITY, INC. shows moderate risk based on this filing. The company's financial performance is subject to market conditions and competition within the laboratory analytical instruments sector, as indicated by its SIC code and business description.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-K to assess Revvity's performance and future outlook.

Financial Highlights

revenue

123,529,821

total Assets

14,697,780,722

net Income

14,697,780,722

Key Numbers

• 14,697,780,722 — Total Assets (As of December 31, 2023)
• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-02-27 — Filing Date (Date filed)
• 3826 — SIC Code (Standard Industrial Classification)
• MA — State of Incorporation (Massachusetts)

Key Players & Entities

• Revvity, Inc. (company) — Filer name
• PerkinElmer Inc (company) — Former company name
• EG&G Inc (company) — Former company name
• Edgerton Germeshausen & Grier Inc (company) — Former company name
• MA (location) — State of incorporation
• Waltham (location) — Business address city
• 02451 (location) — Business address zip
• 781-663-5791 (phone) — Business phone

FAQ

Industry Context

Revvity, Inc. operates within the Laboratory Analytical Instruments industry, as indicated by its SIC code 3826.

Regulatory Implications

As a publicly traded company in the United States, Revvity, Inc. is subject to the regulations of the Securities and Exchange Commission (SEC) and must file annual reports like the 10-K.

What Investors Should Do

1. Analyze Revvity's total assets of $14,697,780,722 as of December 31, 2023.
2. Review the company's history, noting its former names such as PerkinElmer Inc.
3. Confirm the company's primary industry classification (SIC 3826).

Key Dates

• 2024-02-27: 10-K Filing — Annual report filing date
• 2023-12-31: Fiscal Year End — End of reporting period

Year-Over-Year Comparison

This filing is the 2023 Form 10-K for Revvity, Inc., reporting on the fiscal year ending December 31, 2023.

Key Financial Figures

• $1 — ange on Which Registered Common Stock, $1 par value per share RVTY The New York S
• $2.45 billion — or an aggregate purchase price of up to $2.45 billion. We received approximately $2.13 billio
• $2.13 billion — 2.45 billion. We received approximately $2.13 billion in cash proceeds, before transaction co
• $75.0 million — ments. We are entitled to an additional $75.0 million in proceeds as consideration for our ce
• $150.0 million — ed to additional consideration of up to $150.0 million that is contingent on the exit valuatio

Filing Documents

• pki-20231231.htm (10-K) — 2625KB
• a2023exhibit1012.htm (EX-10.12) — 24KB
• a2023exhibit1027.htm (EX-10.27) — 40KB
• a2023exhibit1028.htm (EX-10.28) — 41KB
• a2023exhibit1029.htm (EX-10.29) — 68KB
• a2023exhibit1030.htm (EX-10.30) — 73KB
• a2023exhibit1031.htm (EX-10.31) — 60KB
• a2023exhibit1032.htm (EX-10.32) — 62KB
• a2023exhibit21.htm (EX-21) — 163KB
• a2023exhibit23.htm (EX-23) — 3KB
• a202310kcert-ex_311.htm (EX-31.1) — 13KB
• a202310kcert-ex_312.htm (EX-31.2) — 12KB
• a202310kcert-ex_321.htm (EX-32.1) — 9KB
• a2023exhibit97.htm (EX-97) — 21KB
• image_0.jpg (GRAPHIC) — 89KB
• image_01.jpg (GRAPHIC) — 89KB
• pki-20231231_g1.jpg (GRAPHIC) — 130KB
• 0000031791-24-000004.txt (&nbsp;) — 20089KB
• pki-20231231.xsd (EX-101.SCH) — 195KB
• pki-20231231_cal.xml (EX-101.CAL) — 152KB
• pki-20231231_def.xml (EX-101.DEF) — 1280KB
• pki-20231231_lab.xml (EX-101.LAB) — 2169KB
• pki-20231231_pre.xml (EX-101.PRE) — 1575KB
• pki-20231231_htm.xml (XML) — 2716KB

Risk Factors

Item 1A. Risk Factors 13

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 21

Cybersecurity Disclosures

Item 1C. Cybersecurity Disclosures 21

Properties

Item 2. Properties 22

Legal Proceedings

Item 3. Legal Proceedings 22

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 22 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 25

[Reserved]

Item 6. [Reserved] 26

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 27

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 37

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 39

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 81

Controls and Procedures

Item 9A. Controls and Procedures 81

Other Information

Item 9B. Other Information 84

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 84 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 85

Executive Compensation

Item 11. Executive Compensation 85

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 85

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 85

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 85 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 86

Form 10-K Summary

Item 16. Form 10-K Summary 91

Signatures

Signatures 91 Table of Contents PART I

Business

Item 1. Business Overview We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. As of December 31, 2023, we employed approximately 11,500 employees. Effective as of April 26, 2023, we changed our name from PerkinElmer, Inc. to Revvity, Inc. Effective as of May 16, 2023, we changed the ticker symbol for our common stock to "RVTY" and the ticker symbol for our 1.875% Notes due 2026 to "RVTY 26". Our common stock is listed on the New York Stock Exchange under the symbol "RVTY" and we are a component of the S&P 500 Index. We maintain a website with the address http://www.revvity.com . We are not including the information contained in our website as part of, or incorporating it by reference into, this annual report on Form 10-K. We make available free of charge through our website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to these reports, as soon as reasonably practicable after we electronically file these materials with, or otherwise furnish them to, the Securities and Exchange Commission. Our Strategy Our strategy is to develop and deliver innovative products, services and solutions in high-growth markets that utilize our knowledge and expertise to address customers' critical needs and drive scientific breakthroughs. To execute on our strategy and accelerate revenue growth, we focus on broadening our offerings through both the investment in research and development and the acquisition of innovative technology. Our strategy includes

View Full Filing

View this 10-K filing on SEC EDGAR